State of the Art and Future Prospects in Stem Cell Transplantation
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 341
Special Issue Editor
Interests: bone marrow transplantation; graft versus host disease; complications after stem cell transplantation; reduced intensity stem cell transplantation; HLA-mismatch stem cell transplantation; graft engineering; cell therapy; and gene therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematopoietic Stem Cell Transplantation (HSCT) has emerged as a pivotal tool against hematological malignancies. This Special Issue of "Cells" illuminates state-of-the-art advancements in HSCT, focusing on transformative strides in treating leukemia, lymphoma, and myeloma. Since the inception of allogeneic stem cell transplantation in the mid-20th century, the field has seen remarkable progress. The shift from conventional myeloablative regimens to prevalent reduced-intensity regimens signifies this evolution. The donor landscape has also broadened with cord blood transplantation and the innovative haploidentical HSCT using PTCy. A significant milestone is the recent incorporation of the Minimal Residual Disease (MRD) strategy, making HSCT decisions more scientific and precise. While we celebrate these advancements, challenges like post-transplant relapse, GVHD, and optimal donor selection remain. This Special Issue provides a comprehensive snapshot of the current landscape, emphasizing groundbreaking research and the evolving paradigms in stem cell transplantation for hematological malignancies. As readers explore these articles, from seasoned experts to newcomers, they are invited to discover the innovations shaping the future of hematologic oncology.
Prof. Dr. Shin Mineishi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematopoietic stem cell transplantation
- conditioning
- graft-versus-host disease
- minimal residual disease
- HSCT
